drugset / Trial / NCT00184600

Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes

NCT00184600

Phase 3 Completed 708 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to current OAD (oral anti-diabetic drug) treatment in subjects with type 2 diabetes and to verify the safety of use (number and severity of episodes of hypoglycaemia, body weight and side effects).

Timeline

Start
2004-11
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator biphasic insulin aspart Protein / enzyme biologic Subcutaneous
Comparator insulin aspart Protein / enzyme biologic Subcutaneous
Subject insulin detemir Protein / enzyme biologic Subcutaneous